PMVP — PMV Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1699382 ·
Last close
$1.49
Market Cap
$79.65M
52W High
$1.91
52W Low
$1.02
ADV30
1,050,863
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,881,000 | -18,086,000 | 82,068,000 | 12,469,000 | 10,568,000 |
| Mar 2026 | 0 | — | -19,019,000 | -18,038,000 | 96,562,000 | 39,130,000 | 8,595,000 |
| Dec 2025 | 0 | — | -19,242,000 | -18,037,000 | 116,562,000 | 37,983,000 | 11,850,000 |
| Sep 2025 | 0 | — | -22,522,000 | -21,059,000 | 133,844,000 | 36,337,000 | 12,845,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,990,000
Investing CF
$62,282,000
Financing CF
$495,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.49
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,492,000
Inventory
—
Receivables
—
ST Investments
$54,419,000
EBIT TTM
$-83,662,000
Pretax Income TTM
$-78,319,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -86,206,000 | -77,742,000 | 116,562,000 | 11,850,000 | 104,712,000 | -73,577,000 |
| Dec 2024 | 0 | -85,448,000 | -58,709,000 | 191,288,000 | 15,208,000 | 176,080,000 | -51,282,000 |
| Dec 2023 | 0 | -80,132,000 | -68,960,000 | 252,152,000 | 26,463,000 | 225,689,000 | -55,657,000 |
| Dec 2022 | 0 | -77,040,000 | -73,317,000 | 270,308,000 | 24,280,000 | 246,028,000 | -63,760,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-78,344,000
OpCashFlow TTM
—
Assets (Latest)
$96,562,000
Forward EPS
$-0.97
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $1.52 · call oi: 2,295 · put oi: 2
Expected Move to 2027-01-15:
±$2.45
(161.18%) —
implied range
$-0.93 –
$3.97
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZOMDF | Zomedica Corp. | $79.96M | $0.08 | — |
| RACC | Research Alliance Corp III | $80.08M | $10.30 | — |
| ACRV | Acrivon Therapeutics, Inc. | $80.14M | $1.87 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $79.09M | $1.15 | — |
| PMN | ProMIS Neurosciences Inc. | $82.05M | $9.15 | — |
News headlines (Yahoo Finance, 1h cache)
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
2026-10-05 12:00 · Yahoo
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
2026-09-08 12:00 · Yahoo
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
2026-09-01 13:01 · Yahoo
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
2026-09-01 03:03 · Yahoo
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering
2026-08-31 20:50 · Yahoo
PMV Pharma Announces Proposed Public Offering of Securities
2026-08-31 20:02 · Yahoo
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
2026-08-31 20:01 · Yahoo
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-14 12:00 · Yahoo
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-06-10 13:35 · Yahoo
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
2026-06-02 13:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.